Arlington Capital Partners, a private investment firm based in the Washington, D.C. area, has announced a majority growth investment in Concord Biomedical Sciences and Emerging Technologies (known as CBSET). This Boston-area company is a recognized leader in translational research and product development services for the medical device, pharmaceutical, diagnostic, and broader biomedical research sectors.
CBSET offers a comprehensive range of preclinical testing and regulatory support services, enabling companies to prepare for both FDA and international submissions. Its capabilities span GLP (Good Laboratory Practice) and non-GLP studies, with expertise in areas such as medical devices, drug delivery systems, biologics, cell-based therapies, and combination products. The company also specializes in advanced histopathology, histomorphometry, and image analysis.
CBSET’s integrated research platform includes clinical-grade imaging suites, state-of-the-art laboratory facilities, and a team of highly skilled professionals. This infrastructure allows clients to design and execute complex research programs with tailored endpoints, accelerating the development of innovative medical technologies.
Arlington Capital Partners has a strong history of investing in regulated industries that play essential roles in healthcare, national security, and government systems. In the healthcare space, Arlington focuses on companies that improve patient outcomes, streamline service delivery, and reduce costs. Its portfolio includes TEAM Technologies, Riverpoint Medical, Millstone Medical Outsourcing, and Grand River Aseptic Manufacturing—all of which align with its mission to support life-saving and cost-effective healthcare solutions.
With this investment in CBSET, Arlington aims to help the company scale its operations and expand its impact in the biomedical research field. The partnership is expected to enhance CBSET’s capacity for preclinical research and testing, allowing it to serve a broader range of clients and contribute more significantly to the development of next-generation medical devices and therapeutics.
Advisors: Fairmount Partners served as financial advisor and DLA Piper LLP served as legal advisor to Arlington Capital Partners.
KEY QUOTES:
“As the complexity of medical devices and advanced therapeutics continues to rise amid an increasingly stringent regulatory environment, the need for specialized preclinical research services has never been greater. CBSET has established itself as a trusted partner for leading healthcare innovators across the globe. We look forward to supporting the development of their new state-of-the-art facility while also pursuing complementary acquisitions that will broaden the Company’s service offerings and further strengthen its position as a differentiated market leader.”
Matt Altman, a Managing Partner at Arlington
“As we evolve to meet the needs of an increasingly dynamic industry, we are excited to partner with Arlington in this next chapter. Their deep experience across the medical technology landscape makes them an ideal investment partner as we look to grow and expand our facilities and advance our novel capabilities.”
Peter Markham, CEO and Co-Founder of CBSET
“Our collaboration with Arlington comes at the perfect time as we respond to the evolving needs of the translational community. Together we are redefining approaches to the development and evaluation of innovations in therapeutics – assembling a world class cohort of experts and skilled staff in state-of-the-art, world class facilities for the greatest array of general and specialized tools, resources, and services.”
Dr. Elazer Edelman, Co-Founder of CBSET
“With deep expertise in high-growth areas such as interventional cardiology and structural heart, CBSET is a critical partner to customers in the advancement of innovative and essential treatments and technologies. We look forward to leveraging our own experience in the healthcare manufacturing sector to help the Company accelerate this life-saving work.”
Gordon Auduong, a Managing Director at Arlington
